Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation.
Anticoagulation remains the optimal treatment choice for secondary stroke prevention of AF. The vitamin K antagonists (VKAs) have been the choice of treatment for the last 60 years, but the new oral anticoagulants are now a safe option for treatment of non-valvular AF (NVAF) in the right patient population, taking into account age, renal function, bleeding risk, cardiovascular comorbidities, cost, and drug interactions.